CLINICAL DATA INITIATES PATIENT ENROLLMENT FOR VILAZODONE PHASE 3 CLINICAL TRIAL

Clinical Data, Inc., a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care, announced today that it has initiated patient enrollment in a pivotal Phase 3 clinical research study of vilazodone, a novel dual serotonergic antidepressant compound being studied for treatment of depression.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060330005483&newsLang=en)